{
  "id": 1820720,
  "title": "Alx oncology CEO Jason Lettmann disposes of $4,303 in shares",
  "url": "https://urgent.news/2026/08/18/alx-oncology-ceo-jason-lettmann-disposes-of-4-303-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-18T22:45:56.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/alx-oncology-ceo-jason-lettmann-disposes-of-4303-in-shares-93CH-4866217"
  },
  "original_language": "en",
  "account": "On August 17, 2026, Jason Lettmann, CEO and Director of ALX Oncology Holdings Inc. (ALXO), sold 2,230 shares of the company's common stock. Each share was sold at $1.93, resulting in a total value of $4,303. The purpose of this sale was to meet tax obligations associated with the vesting of restricted stock units.\n\nFollowing the sale, Lettmann now owns 294,379 shares of ALX Oncology Holdings Inc. The stock has shown impressive growth recently, with a one-year increase of over 114% and a year-to-date return of around 84%. At present, the shares are trading at $2.08 per share. This value includes an additional 3,000 shares purchased through the company's employee stock purchase plan on June 30, 2026.\n\nFor a more detailed examination of ALXO's financial situation and future outlook, InvestingPro provides extensive analysis, including Fair Value estimates and a comprehensive Pro Research Report. ALX Oncology has recently appointed Scott Garland as Chairman of the Board of Directors, replacing co-founder Corey Goodman, who is retiring after over ten years with the company. Garland has a 30-year background in the biopharmaceutical industry and has been a member of the ALX Oncology Board since November 2022. Additionally, the company has named Michael Listgarten as General Counsel, both appointments effective immediately.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}